Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
The National Institutes of Health (NIH) has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding. Read more >>
While there is a well-established path from seed funding to exit for web startups, genomics plays with big ambitions require investors with deep pockets and an appetite for risk. Bryan Johnson seemingly has both and has set up a $100 million fund with the objective of turning "crazy" ideas into "viable" businesses.
Microsoft has taken a lead from its co-founder Bill Gates' philanthropic efforts. The computing giant is making its Azure cloud platform available to Ebola researchers who need help with the storage and analysis of data.
Faced with the challenge of how to handle data from the 100,000 exomes it intends to sequence, Regeneron has struck a deal with DNAnexus to access cloud-based infrastructure.The biotech is working with DNAnexus through the Regeneron Genetics Center it established for the sequencing project.
The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
From Our Sister Sites
Pfizer execs can sigh with relief now that a federal court has backed the company's patents on kidney cancer drug Sutent. The med has become increasingly important to Pfizer as sales of off-patent drugs have faded, and so it was alarming to the U.S. drugmaker when generics maker Mylan challenged the patent in 2010 and filed to make its own copy.
The patent cliff may still be taking a toll on Bristol-Myers Squibb, but the company's Q3 sales haul was enough to impress analysts thanks to star performances from a few key new products.